SATB1 in malignant T cells

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

SATB1 in malignant T cells. / Fredholm, Simon Mayland; Willerslev-Olsen, Andreas; Met, Özcan; Kubat, Linda; Gluud, Maria; Mathiasen, Sarah L.; Friese, Christina; Blümel, Edda; Petersen, David Leander; Hu, Tengpeng; Nastasi, Claudia; Lindahl, Lise M.; Buus, Terkild Brink; Krejsgaard, Thorbjørn Frej; Wasik, Mariusz A.; Kopp, Katharina Luise Maria; Koralov, Sergei B.; Persson, Jenny L.; Bonefeld, Charlotte Menne; Geisler, Carsten; Andersen, Anders Woetmann; Iversen, Lars; Becker, Jürgen C.; Ødum, Niels.

I: The Journal of Investigative Dermatology, Bind 138, Nr. 8, 2018, s. 1805-1815.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Fredholm, SM, Willerslev-Olsen, A, Met, Ö, Kubat, L, Gluud, M, Mathiasen, SL, Friese, C, Blümel, E, Petersen, DL, Hu, T, Nastasi, C, Lindahl, LM, Buus, TB, Krejsgaard, TF, Wasik, MA, Kopp, KLM, Koralov, SB, Persson, JL, Bonefeld, CM, Geisler, C, Andersen, AW, Iversen, L, Becker, JC & Ødum, N 2018, 'SATB1 in malignant T cells', The Journal of Investigative Dermatology, bind 138, nr. 8, s. 1805-1815. https://doi.org/10.1016/j.jid.2018.03.1526

APA

Fredholm, S. M., Willerslev-Olsen, A., Met, Ö., Kubat, L., Gluud, M., Mathiasen, S. L., ... Ødum, N. (2018). SATB1 in malignant T cells. The Journal of Investigative Dermatology, 138(8), 1805-1815. https://doi.org/10.1016/j.jid.2018.03.1526

Vancouver

Fredholm SM, Willerslev-Olsen A, Met Ö, Kubat L, Gluud M, Mathiasen SL o.a. SATB1 in malignant T cells. The Journal of Investigative Dermatology. 2018;138(8):1805-1815. https://doi.org/10.1016/j.jid.2018.03.1526

Author

Fredholm, Simon Mayland ; Willerslev-Olsen, Andreas ; Met, Özcan ; Kubat, Linda ; Gluud, Maria ; Mathiasen, Sarah L. ; Friese, Christina ; Blümel, Edda ; Petersen, David Leander ; Hu, Tengpeng ; Nastasi, Claudia ; Lindahl, Lise M. ; Buus, Terkild Brink ; Krejsgaard, Thorbjørn Frej ; Wasik, Mariusz A. ; Kopp, Katharina Luise Maria ; Koralov, Sergei B. ; Persson, Jenny L. ; Bonefeld, Charlotte Menne ; Geisler, Carsten ; Andersen, Anders Woetmann ; Iversen, Lars ; Becker, Jürgen C. ; Ødum, Niels. / SATB1 in malignant T cells. I: The Journal of Investigative Dermatology. 2018 ; Bind 138, Nr. 8. s. 1805-1815.

Bibtex

@article{e025cf5bb3ed4bffa605d8c1651eb730,
title = "SATB1 in malignant T cells",
abstract = "Deficient expression of Suppressor Special AT-rich Binding-1 (SATB1) hampers thymocyte development and results in inept T cell lineages. Recent data implicate dysregulated SATB1 expression in the pathogenesis of mycosis fungoides (MF), the most frequent variant of cutaneous T cell lymphoma (CTCL). Here we report on a disease-stage-associated decrease of SATB1 expression and an inverse expression of STAT5 and SATB1 in situ. Importantly, STAT5 inhibited SATB1 expression through induction of miR-155. Decreased SATB1 expression triggered enhanced expression of IL-5 and IL-9 (but not IL-6 and IL-32) whereas increased SATB1 expression had the opposite effect indicating that the mir-155 target SATB1 is a repressor of IL-5 and IL-9 in malignant T cells. In accordance, inhibition of STAT5, and its upstream activator Janus Kinase-3 (Jak3), triggered increased SATB1 expression and a concomitant suppression of IL-5 and IL-9 expression in malignant T cells. In conclusion, we provide a mechanistic link between the proto-oncogenic Jak3/STAT5/miR-155 pathway, SATB1, and cytokines linked to CTCL severity and progression indicating that SATB1 dysregulation is involved in CTCL pathogenesis.",
author = "Fredholm, {Simon Mayland} and Andreas Willerslev-Olsen and {\"O}zcan Met and Linda Kubat and Maria Gluud and Mathiasen, {Sarah L.} and Christina Friese and Edda Bl{\"u}mel and Petersen, {David Leander} and Tengpeng Hu and Claudia Nastasi and Lindahl, {Lise M.} and Buus, {Terkild Brink} and Krejsgaard, {Thorbj{\o}rn Frej} and Wasik, {Mariusz A.} and Kopp, {Katharina Luise Maria} and Koralov, {Sergei B.} and Persson, {Jenny L.} and Bonefeld, {Charlotte Menne} and Carsten Geisler and Andersen, {Anders Woetmann} and Lars Iversen and Becker, {J{\"u}rgen C.} and Niels {\O}dum",
note = "Copyright {\circledC} 2018 The Authors. Published by Elsevier Inc. All rights reserved.",
year = "2018",
doi = "10.1016/j.jid.2018.03.1526",
language = "English",
volume = "138",
pages = "1805--1815",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "nature publishing group",
number = "8",

}

RIS

TY - JOUR

T1 - SATB1 in malignant T cells

AU - Fredholm, Simon Mayland

AU - Willerslev-Olsen, Andreas

AU - Met, Özcan

AU - Kubat, Linda

AU - Gluud, Maria

AU - Mathiasen, Sarah L.

AU - Friese, Christina

AU - Blümel, Edda

AU - Petersen, David Leander

AU - Hu, Tengpeng

AU - Nastasi, Claudia

AU - Lindahl, Lise M.

AU - Buus, Terkild Brink

AU - Krejsgaard, Thorbjørn Frej

AU - Wasik, Mariusz A.

AU - Kopp, Katharina Luise Maria

AU - Koralov, Sergei B.

AU - Persson, Jenny L.

AU - Bonefeld, Charlotte Menne

AU - Geisler, Carsten

AU - Andersen, Anders Woetmann

AU - Iversen, Lars

AU - Becker, Jürgen C.

AU - Ødum, Niels

N1 - Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

PY - 2018

Y1 - 2018

N2 - Deficient expression of Suppressor Special AT-rich Binding-1 (SATB1) hampers thymocyte development and results in inept T cell lineages. Recent data implicate dysregulated SATB1 expression in the pathogenesis of mycosis fungoides (MF), the most frequent variant of cutaneous T cell lymphoma (CTCL). Here we report on a disease-stage-associated decrease of SATB1 expression and an inverse expression of STAT5 and SATB1 in situ. Importantly, STAT5 inhibited SATB1 expression through induction of miR-155. Decreased SATB1 expression triggered enhanced expression of IL-5 and IL-9 (but not IL-6 and IL-32) whereas increased SATB1 expression had the opposite effect indicating that the mir-155 target SATB1 is a repressor of IL-5 and IL-9 in malignant T cells. In accordance, inhibition of STAT5, and its upstream activator Janus Kinase-3 (Jak3), triggered increased SATB1 expression and a concomitant suppression of IL-5 and IL-9 expression in malignant T cells. In conclusion, we provide a mechanistic link between the proto-oncogenic Jak3/STAT5/miR-155 pathway, SATB1, and cytokines linked to CTCL severity and progression indicating that SATB1 dysregulation is involved in CTCL pathogenesis.

AB - Deficient expression of Suppressor Special AT-rich Binding-1 (SATB1) hampers thymocyte development and results in inept T cell lineages. Recent data implicate dysregulated SATB1 expression in the pathogenesis of mycosis fungoides (MF), the most frequent variant of cutaneous T cell lymphoma (CTCL). Here we report on a disease-stage-associated decrease of SATB1 expression and an inverse expression of STAT5 and SATB1 in situ. Importantly, STAT5 inhibited SATB1 expression through induction of miR-155. Decreased SATB1 expression triggered enhanced expression of IL-5 and IL-9 (but not IL-6 and IL-32) whereas increased SATB1 expression had the opposite effect indicating that the mir-155 target SATB1 is a repressor of IL-5 and IL-9 in malignant T cells. In accordance, inhibition of STAT5, and its upstream activator Janus Kinase-3 (Jak3), triggered increased SATB1 expression and a concomitant suppression of IL-5 and IL-9 expression in malignant T cells. In conclusion, we provide a mechanistic link between the proto-oncogenic Jak3/STAT5/miR-155 pathway, SATB1, and cytokines linked to CTCL severity and progression indicating that SATB1 dysregulation is involved in CTCL pathogenesis.

U2 - 10.1016/j.jid.2018.03.1526

DO - 10.1016/j.jid.2018.03.1526

M3 - Journal article

C2 - 29751003

VL - 138

SP - 1805

EP - 1815

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 8

ER -

ID: 197098365